Successful decolonization of meticillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol

Journal of Hospital Infection

Volumn 65, Issue 3, 2007, Pages 231-236

  Macfarlane, M ^a   Leavy, A ^a   McCaughan, J ^a   Fair, R ^a   Reid, A J M ^a  

^a ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

CF; Cystic fibrosis; Infection control; Lung infection; MRSA; Paediatric; Staphylococcus aureus

Indexed keywords

CHLORHEXIDINE; FLUCLOXACILLIN; FUSIDIC ACID; METICILLIN; OXACILLIN; PSEUDOMONIC ACID; RIFAMPICIN; TEICOPLANIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PEDIATRICS; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; INFANT; MICROBIOLOGY; PENICILLIN RESISTANCE; PNEUMONIA; PRESCHOOL CHILD; SPUTUM; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; FEMALE; FUSIDIC ACID; HUMANS; INFANT; MALE; METHICILLIN RESISTANCE; PNEUMONIA; RIFAMPIN; SEVERITY OF ILLNESS INDEX; SPUTUM; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN;

EID: 33847047400     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2006.10.011     Document Type: Article

References (11)

1. Boxerbaum B., Jacobs M.R., and Cechner R.L. Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmonol 4 (1988) 159-163 Erratum in: Pediatr Pulmonol 1988;5:66.
2. Thomas S.R., Gyi K.M., Gaya H., and Hodson M.E. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect 40 (1998) 203-209
3. Rao G., Gaya H., Hodson M., et al. MRSA in cystic fibrosis. J Hosp Infect 40 (1998) 179-191
4. Solis A., Brown D., Hughes J., Van Saene H.K., and Heaf D.P. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol protocol. Pediatr Pulmonol 36 (2003) 189-195
5. Garske L.A., Kidd T.J., Gan R., et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 56 (2004) 208-214
6. Máiz L., Cantón R., Mir N., Baquero F., and Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 26 (1998) 287-289
7. Wethers L. Aerosolized vancomycin for the treatment of MRSA infection in cystic fibrosis. Pediatr Infect Dis 9 (1990) 220-221
8. Frederiksen B., Koch C., and Hoiby N. Antibiotic treatment at time of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration in pulmonary function in patients with cystic fibrosis. Pediatr Pulmonol 23 (1997) 330-335
9. Downey D.G., Kidd T.J., Coulter C., and Bell S.C. MRSA eradication in a healthcare worker with cystic fibrosis; re-emergence or re-infection?. J Cyst Fibros 4 (2005) 205-207
10. Wood M.J. Comparative safety of teicoplanin and vancomycin. J Chemother 12 Suppl. 5 (2000) 21-25
11. Nadesalingam K., Conway S.P., and Denton M. Risk factors for acquisition of methicillin-resistant Staphyloccus aureus (MRSA) by patients with cystic fibrosis. J Cystic Fibros 4 (2005) 49-52